Santaris Acquisition By Roche May Help VCs Back New Biotechs In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche paying $450 million for Danish biotech Santaris is likely to fuel excitement around RNA-targeting technologies and may generate a liquidity boost for Europe’s VC sector.
You may also be interested in...
Deal Watch: Endo Elbows In On Valeant’s Pursuit Of Salix
Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.
Biopharma Dealmaking Quarterly Statistics, Q3 2014
Biopharma financing dropped 22% in Q3 to $5.65 billion. In the largest M&A, Roche bulked up on rare diseases, gaining Esbriet through its $8 billion takeover of InterMune; Sanofi dominated in alliance dealmaking.
European Notebook: EMA Meetings Go (Somewhat) Public; Walgreens’ Global Reach; Scottish Independence?
The European Medicines Agency moves closer to U.S.-style advisory committee meetings in public; two national referendums next month could hit Scotland’s biotech industry and Switzerland’s health insurance sector.